Partnership Opportunities

In today’s rapidly growing ADC landscape, the opportunity to identify novel targets has become a priority in order to leave a prominent mark on the field. The 4th ADC Target Selection Summit is the only industry-specific forum providing the industry with scientific and strategic insights to transform ADC target selection by identifying novel and repurposing clinically validated targets.

Last year, over 100+ attendees were in the room from Seagen, AstraZeneca, Merck, Zymeworks, AbbVie, Bolt Biotherapeutics, and many more; who are working exclusively in biology, discovery, translational, target identification and validation.

Don’t miss this opportunity to gain unparalleled visibility to this audience looking for partnerships and collaborations that can aid them to better inform target selection and balance risk in ADC pipelines to progress them into the clinic and ultimately to market.

Find Out More Here

Screenshot 2024-09-24 093751aa

What Are ADC Target Experts Seeking?

https://adc-targetselection.com/wp-content/uploads/sites/558/2023/07/cropped-33236-ADC-Target-Selection-Summit-Logo_FINAL-90x90-1.png

Artificial Intelligence and Computational Biology Expertise: Solution providers with capabilities in artificial intelligence, bioinformatics, computational biology and machine learning, allowing for advanced target selection platforms, driving efficiency and speed of the process to uncover the untapped potential of ADC therapeutics.

https://adc-targetselection.com/wp-content/uploads/sites/558/2023/07/cropped-33236-ADC-Target-Selection-Summit-Logo_FINAL-90x90-1.png

Single Cell RNA Sequencing Solutions: The ability to combine in-depth sequencing data with mechanistic target understanding to characterize the properties of prospective targets and indicate that the selection process is in alignment with specific ADC.

https://adc-targetselection.com/wp-content/uploads/sites/558/2023/07/cropped-33236-ADC-Target-Selection-Summit-Logo_FINAL-90x90-1.png

Antibody Discovery & Providers: ADC developers with expertise in target selection are looking to partner with high quality antibody discovery or manufacturing organizations to complement their target of choice and in-license antibodies.

https://adc-targetselection.com/wp-content/uploads/sites/558/2023/07/cropped-33236-ADC-Target-Selection-Summit-Logo_FINAL-90x90-1.png

Histology & Immunohistochemistry Services (IHC): ADC developers are seeking highly specialized IHC providers to see how their drug is binding with the desired target in a preclinical setting, often outsourcing this stage of their development.

If you are an industry leader in any of the above, make sure to showcase your services and form new connections and partnerships at this unique and focused forum.

Benefits of Partnering With Us

  • Meet your 2025 commercial objectives early and educate decision-makers on how your expertise can help ADC developers progress their drugs to clinic, and ultimately to market
  • Showcase your expertise to leading ADC developers by securing an exhibition booth to set yourself as to go-to service provider in the ADC target community
  • Demonstrate thought leadership and drive brand exposure by securing a speaking slot on the agenda to connect with the community and generate partnerships
  • Maximize the balance of content and networking to generate leads and build new relationships with industry pioneers

Who Will You Meet:

Spex Stats